NASDAQ:CLOV - Nasdaq - US18914F1030 - Common Stock - Currency: USD
4.4
-0.09 (-2%)
The current stock price of CLOV is 4.4 USD. In the past month the price decreased by -5.98%. In the past year, price increased by 387.37%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
UNH | UNITEDHEALTH GROUP INC | 16.71 | 429.24B | ||
ELV | ELEVANCE HEALTH INC | 11.68 | 89.31B | ||
HUM | HUMANA INC | 15.81 | 30.87B | ||
CNC | CENTENE CORP | 8.12 | 28.60B | ||
MOH | MOLINA HEALTHCARE INC | 12.53 | 15.75B | ||
HQY | HEALTHEQUITY INC | 35.37 | 9.41B | ||
ALHC | ALIGNMENT HEALTHCARE INC | N/A | 2.53B | ||
PGNY | PROGYNY INC | 40 | 1.98B | ||
NEUE | NEUEHEALTH INC | 5.57 | 60.93M |
Clover Health Investments Corp. provides healthcare insurance services. The company is headquartered in Franklin, Tennessee and currently employs 552 full-time employees. The company went IPO on 2020-06-12. The firm is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. The company offers a software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
CLOVER HEALTH INVESTMENTS CO
3401 Mallory Lane, Suite 210, Suite 320
Franklin TENNESSEE 37067 US
CEO: Vivek Garipalli
Employees: 552
Company Website: https://www.cloverhealth.com/
Investor Relations: http://investors.cloverhealth.com/financial-information/sec-filings
Phone: 12014322133
The current stock price of CLOV is 4.4 USD. The price decreased by -2% in the last trading session.
The exchange symbol of CLOVER HEALTH INVESTMENTS CO is CLOV and it is listed on the Nasdaq exchange.
CLOV stock is listed on the Nasdaq exchange.
11 analysts have analysed CLOV and the average price target is 4.17 USD. This implies a price decrease of -5.19% is expected in the next year compared to the current price of 4.4. Check the CLOVER HEALTH INVESTMENTS CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CLOVER HEALTH INVESTMENTS CO (CLOV) has a market capitalization of 2.20B USD. This makes CLOV a Mid Cap stock.
CLOVER HEALTH INVESTMENTS CO (CLOV) currently has 552 employees.
CLOVER HEALTH INVESTMENTS CO (CLOV) has a support level at 4.31. Check the full technical report for a detailed analysis of CLOV support and resistance levels.
The Revenue of CLOVER HEALTH INVESTMENTS CO (CLOV) is expected to decline by -24.3% in the next year. Check the estimates tab for more information on the CLOV EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CLOV does not pay a dividend.
CLOVER HEALTH INVESTMENTS CO (CLOV) will report earnings on 2025-03-04, after the market close.
CLOVER HEALTH INVESTMENTS CO (CLOV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
The outstanding short interest for CLOVER HEALTH INVESTMENTS CO (CLOV) is 3.88% of its float. Check the ownership tab for more information on the CLOV short interest.
ChartMill assigns a technical rating of 8 / 10 to CLOV. When comparing the yearly performance of all stocks, CLOV is one of the better performing stocks in the market, outperforming 98.86% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CLOV. CLOV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months CLOV reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 60% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -13.99% | ||
ROE | -26.71% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 76% to CLOV. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 72.76% and a revenue growth -24.3% for CLOV